-transparent.png){kind=logo}
The effects of human calcitonin on bone mineral content and certain biochemical markers of bone metabolism were evaluated in a 2-12 month treatment period in seven patients with osteogenesis imperfecta. S-calcium, S-alkaline phosphatase, S-immuno-reactive parathyroid hormone and the urinary excretion of calcium were found to be within the normal range before and during the treatment period. After 4-5 months of therapy, a slight increase in the urinary excretion of hydroxyproline was observed, but the values were still within the normal range. The bone mineral content, measured in the forearm, remained unchanged during the treatment period. Side effects were common, in two cases resulting in discontinuation of the treatment. We concluded that, with the dose of human calcitonin used, it was impossible to detect any beneficial effect in patients with osteogenesis imperfecta.
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
April 1973,
British medical journal,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
January 1974,
Current therapeutic research, clinical and experimental,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
May 1972,
The Journal of pediatrics,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
March 1979,
Minerva pediatrica,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
January 1982,
Pediatria polska,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
January 1989,
The Journal of international medical research,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
December 1977,
The Journal of pediatrics,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
November 1979,
The Journal of pediatrics,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
April 1984,
Pediatrics,
U Pedersen, and
P Charles, and
H H Hansen, and
O Elbrønd
September 1972,
JAMA,
